Cilazapril is an ACE inhibitor used for the management of hypertension and heart failure. It belongs to the angiotensin-converting enzyme inhibitors (ACE inhibitors) class of drugs.
- Mechanism
- Curator reviewed
Cilazapril is a pyridazine ACE inhibitor. It competes with angiotensin I for binding at the angiotensin-converting enzyme, blocking the conversion of angiotensin I to angiotensin II. As angiotensin II is a vasoconstrictor and a negative feedback mediator for renin activity, lower angiotensin II levels results in a decrease in blood pressure, an increase in renin activity, and stimulation of baroreceptor reflex mechanisms. Kininase II, an enzyme which degrades the vasodilator bradykinin, is identical to ACE and may also be inhibited.
- Primary indication
- Cilazapril is an ACE inhibtor class drug used in the treatment of hypertension and heart failure.Curator reviewed · 4 structured indications
- Formula / weight
- C22H31N3O5 · 417.4986 g/mol (avg)
- First approval
- Canada, 2006
- Code names
- Ro 31-2848
- Brand names
Resolves to
HHHKFGXWKKUNCY-FHWLQOOXSA-NSMILESCCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@H]1CCCN2CCC[C@H](N2C1=O)C(O)=OWhat you can answer from here — as of September 12, 2026
Which drugs share a target with Cilazapril, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account